GARY LYMAN was named co-director of The Hutchinson Institute for Cancer Outcomes Research, based at the Fred Hutchinson Cancer Research Center. He will co-lead with Scott Ramsey, a member of the Cancer Prevention Program in the Public Health Sciences Division at Fred Hutch.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
